RPID logo

RAPID MICRO BIOSYSTEMS INC-A

RPIDNASDAQ
πŸ† #3663 by market capEarnings Nov 6US Equity
$1.66β–Ό $0.03 (βˆ’1.78%)
Live
1hβ€”
24hβ–Ό 1.8%
7dβ–Ό 20.6%
14dβ–Ό 19.2%
30dβ–Ό 17.0%
1yβ–Ό 39.0%
🏦Market Cap
$75M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+19.7%
Healthy
πŸ“ŠGross Margin
10.0%
Thin
πŸ’΅FCF Margin
-114.8%
Thin
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.64 – $1.69
52-Week Range
$1.58 – $4.94
Volume
$2.57B
Avg Volume
$2.45B
Shares Outstanding
45.3M
Next Earnings
Oct 10, 2026

Fundamentals Snapshot

Annual Revenue
$34M
Last Q Revenue
$8M
P/E Ratio
-1.5
P/S Ratio
2.1x
EPS (TTM)
$-1.09
Dividend Yield
0.00%

Why Investors Own RPID

  • βœ“High-growth profile β€” revenue up +0.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 80% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$34Mβ–Ό βˆ’4.2% YoY
Gross Margin (TTM)
80.0%β–² +1.8% YoY
Operating Income (TTM)
$11Mβ–Ό βˆ’4.2% YoY
Free Cash Flow (TTM)
$6Mβ–Ό βˆ’4.2% YoY

About RAPID MICRO BIOSYSTEMS INC-A

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
56/100

Analyst Price Target

β“˜
Average Target
$1.70
β–² +2.5% Upside
High Target$1.97
Low Target$1.38
Based on 33 analysts

Latest News & Updates